{"id":"clopidogrel-tapering","safety":{"commonSideEffects":[{"rate":null,"effect":"Stent thrombosis"},{"rate":null,"effect":"Recurrent myocardial infarction"},{"rate":null,"effect":"Bleeding"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a thienopyridine P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation. Tapering protocols investigate whether gradual dose reduction or discontinuation maintains antithrombotic benefit while reducing bleeding risk in patients who have completed an initial intensive dual antiplatelet therapy period, particularly after acute coronary syndrome or percutaneous coronary intervention.","oneSentence":"Clopidogrel tapering is a dosing strategy that gradually reduces clopidogrel exposure after dual antiplatelet therapy to assess safety and efficacy of de-escalation in cardiovascular patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:30:17.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"De-escalation strategy in acute coronary syndrome post-percutaneous coronary intervention"},{"name":"Assessment of dual antiplatelet therapy duration optimization"}]},"trialDetails":[{"nctId":"NCT00640679","phase":"PHASE4","title":"Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation","status":"TERMINATED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2008-04","conditions":"Coronary Artery Disease","enrollment":782}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plavix"],"phase":"marketed","status":"active","brandName":"Clopidogrel Tapering","genericName":"Clopidogrel Tapering","companyName":"Deutsches Herzzentrum Muenchen","companyId":"deutsches-herzzentrum-muenchen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopidogrel tapering is a dosing strategy that gradually reduces clopidogrel exposure after dual antiplatelet therapy to assess safety and efficacy of de-escalation in cardiovascular patients. Used for De-escalation strategy in acute coronary syndrome post-percutaneous coronary intervention, Assessment of dual antiplatelet therapy duration optimization.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}